Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03091192 · ClinicalTrials.gov registry record · Phase 3
Savolitinib vs. Sunitinib in MET-driven PRCC.
A Phase 3 study of Kidney Diseases and Carcinoma, Renal Cell, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT03091192: Active Phase 3 study of Kidney Diseases and Carcinoma, Renal Cell, sponsored by AstraZeneca.
NCT03091192 is a Phase 3 study of Kidney Diseases and Carcinoma, Renal Cell that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 60 participants, below the 1,784-participant average among 38 other Kidney Diseases trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03091192, a Phase 3 study of Kidney Diseases and Carcinoma, Renal Cell, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed for patients diagnosed with MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma. The purpose of this study is to see if an investigational new anti-cancer medication, savolitinib, is effective in treating patients with MET-driven PRCC, how it compares with another medication frequently used to treat this disease called sunitinib, and what side effects it might cause.
Primary Outcome
Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Progressive Disease (PD): \>= 20% increase in the sum of diameters of TLs and an absolute increase in sum of diameters of \>=5mm (compared to the previous minimum sum) or progression of NTLs or a new lesion. PFS is the time from date of randomisation until the date of PD (defined by Recist 1.1 and confirmed by BICR) or death (by any cause in the absence of progression) regardless of whether the patient withdre
Conditions Studied
Interventions
- DRUG Sunitinib
- DRUG Savolitinib
Study Locations (20)
Other
- Research Site - Barretos
- Research Site - Curitiba
- Research Site - Passo Fundo
- Research Site - Pelotas
- Research Site - Porto Alegre
- Research Site - Porto Alegre
- Research Site - Porto Alegre
- Research Site - Rio de Janeiro
- Research Site - São José do Rio Preto
- Research Site - São Paulo
- Research Site - São Paulo
- Research Site - Bordeaux
California
- Research Site - La Jolla
Georgia
- Research Site - Atlanta
Illinois
- Research Site - Chicago
Iowa
- Research Site - Iowa City
Massachusetts
- Research Site - Boston
Missouri
- Research Site - Kansas City
New York
- Research Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-07-25 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 3 |
What the registry record for NCT03091192 still lists
NCT03091192 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,784-participant average among 38 other Kidney Diseases trials with a reported enrollment target (97% lower).
The record links to 8 conditions, with Kidney Diseases appearing as the primary indexed condition, and to 2 interventions - of which Sunitinib is the first listed.
NCT03091192 names 20 study sites across 9 states, led by Other, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT03091192 about?
NCT03091192 is a clinical study titled "Savolitinib vs. Sunitinib in MET-driven PRCC.". This study is designed for patients diagnosed with MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma. The purpose of this study is to see if an investigational new anti-cancer medication, savolitinib, is effective in treating patients with MET-driven PRCC, ho...
What is the current status of trial NCT03091192?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2017-07-25. Estimated completion is 2026-12-31.
What conditions does trial NCT03091192 study?
This clinical trial studies the following conditions: Kidney Diseases, Carcinoma, Renal Cell, Carcinoma, Neoplasms by Site, Kidney Neoplasms.
What interventions are being tested in trial NCT03091192?
The interventions under investigation include: Sunitinib (DRUG), Savolitinib (DRUG).
Who is sponsoring clinical trial NCT03091192?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03091192 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, Iowa, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03091192's enrollment target sits among peer trials
60 28th of 38 higher than 10 of 38 other Kidney Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
RECRUITING · Phase 3
-
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
RECRUITING · Phase 3
-
Long Term Extension Study in Patients With Primary Hyperoxaluria
ACTIVE NOT RECRUITING · Phase 3
-
Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring
COMPLETED · Phase 3
-
Collaborative Learning to Achieve Refined Interventions for Emory: Kidney Disease
RECRUITING · NA
-
Rutgers University Study of the Genetics of Kidney Disease
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI